Entity

Time filter

Source Type

Wilmington, DE, United States

Incyte is a pharmaceutical company based in Alapocas, Delaware. Incyte has one drug which has been approved by the U.S. Food and Drug Administration and has been prescribed to several thousands of patients in the United States, Jakafi.In 2014, Incyte named Hervé Hoppenot to the posts of President and CEO. Hoppenot had previously served as the President of Novartis Oncology; he had been with Novartis since 2003. Wikipedia.


This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.


This invention relates to JAK selective inhibitors for use in treatment of chronic neutrophilic leukemia and atypical chronic myeloid leukemia in patients.


This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.


Patent
Incyte | Date: 2015-02-12

The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.


Patent
Incyte | Date: 2015-02-12

The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Discover hidden collaborations